Hematological event-free survival (EFS) of patients with AL amyloidosis treated with frontline Dara-VCD or Dara-VD. Kaplan-Meier survival curves according to t(11;14) status (A) and 1q gain status (B). See Figure 3A-B in the article by Chakraborty et al that begins on page 2613.